Product Description
Tirzepatide is a cutting-edge dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This novel peptide represents the next generation of metabolic research compounds, offering researchers a unique tool to study dual incretin receptor activation.
What Makes Tirzepatide Unique?
Unlike single-target GLP-1 agonists like semaglutide, tirzepatide activates both GIP and GLP-1 receptors simultaneously. This dual mechanism provides researchers with a more comprehensive model for studying metabolic regulation, glucose homeostasis, and energy balance.
Molecular Structure
Tirzepatide is a 39-amino acid synthetic peptide based on the native GIP sequence. It features:
- Cβββ
HβββNβ
βOββ molecular formula
- 4813.5 g/mol molecular weight
- C20 fatty diacid moiety for extended half-life (~5 days)
- Dual receptor binding - GIP and GLP-1 receptors
- Optimized pharmacokinetics for once-weekly administration in research models
Research Applications
Tirzepatide is extensively studied in metabolic research for:
- Glucose metabolism and insulin sensitivity studies
- Energy expenditure and thermogenesis research
- Appetite regulation and satiety signaling
- Lipid metabolism and adipose tissue function
- Cardiovascular metabolic effects
- Comparative studies with single-target GLP-1 agonists
Quality Assurance
Our Tirzepatide 5mg undergoes rigorous quality control:
- HPLC Analysis: Verified 99.2%+ purity
- Mass Spectrometry: Confirmed molecular weight and structure
- Endotoxin Testing: <0.1 EU/mg
- Sterility Testing: Passes USP standards
- Third-Party Verification: Independent lab COA included
Storage & Handling
Lyophilized (Powder): Store at -20Β°C to -80Β°C. Stable for 24+ months when properly stored. Protect from light and moisture.
Reconstituted: Store at 2-8Β°C (refrigerated). Use within 28 days. Do not freeze once reconstituted.
Reconstitution Protocol
For research applications, tirzepatide is typically reconstituted with bacteriostatic water:
- Allow vial to reach room temperature (15-20 minutes)
- Add 2ml bacteriostatic water slowly down the side of the vial
- Gently swirl (do not shake) until fully dissolved
- Final concentration: 2.5mg/ml
- Store reconstituted solution at 2-8Β°C
Why Choose Our Tirzepatide?
- Pharmaceutical-Grade Synthesis: Manufactured using solid-phase peptide synthesis (SPPS) in cGMP facilities
- Batch Consistency: Every batch tested to ensure consistent purity and potency
- Complete Documentation: COA, HPLC chromatogram, and MS data included
- Fast Shipping: Orders ship within 24 hours with cold chain packaging
- Research Support: Technical documentation and reconstitution guides provided
β οΈ Important Research Notice
Tirzepatide is a potent metabolic research compound. This product is intended solely for in vitro research and laboratory applications. It is not approved for human consumption, clinical use, or veterinary applications. Researchers must comply with all applicable regulations and institutional guidelines.
Research Applications & Mechanisms
Dual Incretin Receptor Activation
Tirzepatide's unique dual-agonist mechanism provides researchers with a powerful tool to study the synergistic effects of GIP and GLP-1 receptor activation:
GIP Receptor Activation
- Insulin Secretion: Glucose-dependent insulin release from pancreatic Ξ²-cells
- Glucagon Suppression: Reduced glucagon secretion from Ξ±-cells
- Adipose Tissue Effects: Enhanced lipid storage and reduced lipolysis
- Bone Metabolism: Potential effects on bone formation and remodeling
- CNS Effects: Appetite regulation and energy homeostasis
GLP-1 Receptor Activation
- Insulin Secretion: Potent glucose-dependent insulin release
- Gastric Emptying: Delayed gastric emptying and increased satiety
- Appetite Suppression: Central and peripheral appetite regulation
- Glucagon Inhibition: Suppression of inappropriate glucagon secretion
- Cardiovascular Effects: Potential cardioprotective mechanisms
Key Research Areas
1. Metabolic Research
Tirzepatide is extensively studied in metabolic research models:
- Glucose Homeostasis: Superior glycemic control compared to single-target agonists in preclinical models
- Insulin Sensitivity: Enhanced insulin sensitivity in peripheral tissues
- Beta-Cell Function: Preservation and potential enhancement of Ξ²-cell mass and function
- Hepatic Glucose Production: Reduced hepatic glucose output
2. Energy Balance Studies
Research demonstrates significant effects on energy metabolism:
- Energy Expenditure: Increased thermogenesis and metabolic rate
- Fat Oxidation: Enhanced lipid utilization for energy
- Body Composition: Preferential loss of adipose tissue vs. lean mass
- Appetite Regulation: Reduced food intake through multiple mechanisms
3. Cardiovascular Metabolic Research
Emerging research explores cardiovascular effects:
- Blood Pressure: Modest reductions in systolic blood pressure
- Lipid Profiles: Improvements in triglycerides and cholesterol
- Inflammation: Reduced inflammatory markers (CRP, IL-6)
- Endothelial Function: Potential improvements in vascular health
4. Comparative Pharmacology
Tirzepatide provides unique opportunities for comparative studies:
- vs. Semaglutide: Head-to-head comparisons of dual vs. single agonism
- vs. Liraglutide: Differences in receptor selectivity and duration
- vs. Native Incretins: Synthetic modifications and enhanced stability
- Dose-Response Studies: Characterization of optimal dosing ranges
Pharmacokinetic Profile
Understanding tirzepatide's PK properties is crucial for research design:
- Half-Life: ~5 days (allows once-weekly dosing in research models)
- Tmax: 8-72 hours post-administration
- Bioavailability: 80% (subcutaneous administration)
- Metabolism: Proteolytic cleavage, similar to endogenous peptides
- Elimination: Renal and proteolytic degradation
Research Dosing Considerations
Tirzepatide research typically employs escalating dose protocols:
- Starting Doses: 2.5mg weekly (research models)
- Titration: Gradual increases every 4 weeks
- Maintenance Doses: 5-15mg weekly range
- Maximum Studied: Up to 15mg weekly in research
Synergistic Effects with Other Compounds
Research explores tirzepatide combinations:
- Metformin: Additive effects on glucose metabolism
- SGLT2 Inhibitors: Complementary mechanisms for metabolic research
- Insulin: Reduced insulin requirements in research models
- Other Peptides: Potential synergies with growth hormone peptides
π Research Note
Tirzepatide represents a significant advancement in incretin-based research. The dual GIP/GLP-1 mechanism provides superior metabolic effects compared to single-target agonists in preclinical studies. Researchers should consider the extended half-life when designing experimental protocols and allow adequate washout periods between treatments.
Research Dosing Guidelines
β οΈ Research Use Only
The following information is provided for research purposes only. This product is not intended for human consumption or clinical use. All dosing information is based on published research literature and preclinical studies.
Reconstitution Instructions
Proper reconstitution is critical for research accuracy:
Standard Protocol (2.5mg/ml concentration):
- Preparation: Remove vial from freezer and allow to reach room temperature (15-20 minutes)
- Supplies Needed:
- 5mg tirzepatide vial (lyophilized)
- 2ml bacteriostatic water (0.9% benzyl alcohol)
- Sterile syringe (3ml or larger)
- Alcohol swabs
- Reconstitution Steps:
- Clean vial top with alcohol swab
- Draw 2ml bacteriostatic water into syringe
- Inject water slowly down the side of the vial (not directly onto powder)
- Gently swirl vial in circular motion (DO NOT SHAKE)
- Allow 2-3 minutes for complete dissolution
- Inspect solution - should be clear and colorless
- Final Concentration: 2.5mg/ml (0.1ml = 0.25mg, 0.2ml = 0.5mg, etc.)
Research Dosing Protocols
Based on published research, tirzepatide is typically administered using escalating dose protocols:
Protocol 1: Standard Titration (Research Model)
| Week |
Dose |
Volume (2.5mg/ml) |
Frequency |
| 1-4 |
2.5mg |
1.0ml |
Once weekly |
| 5-8 |
5.0mg |
2.0ml (1 vial) |
Once weekly |
| 9-12 |
7.5mg |
3.0ml (1.5 vials) |
Once weekly |
| 13+ |
10-15mg |
4-6ml (2-3 vials) |
Once weekly |
Protocol 2: Accelerated Titration
Some research models use faster titration:
- Week 1-2: 2.5mg weekly
- Week 3-4: 5.0mg weekly
- Week 5-6: 7.5mg weekly
- Week 7+: 10mg weekly (maintenance)
Protocol 3: Conservative Approach
For sensitive research models or initial studies:
- Week 1-6: 2.5mg weekly
- Week 7-12: 5.0mg weekly
- Week 13-18: 7.5mg weekly
- Week 19+: 10mg weekly (if tolerated)
Administration Guidelines
Subcutaneous Injection (Research Standard):
- Injection Sites: Abdomen, thigh, or upper arm (rotate sites)
- Needle Size: 29-31G, 5-8mm length
- Technique: Pinch skin, insert at 45-90Β° angle, inject slowly
- Timing: Can be administered any time of day, with or without food
- Consistency: Same day each week recommended for research protocols
Dosing Calculations
Using 2.5mg/ml concentration (5mg vial + 2ml water):
- 0.25mg dose: 0.1ml (10 units on insulin syringe)
- 0.5mg dose: 0.2ml (20 units)
- 1.0mg dose: 0.4ml (40 units)
- 2.5mg dose: 1.0ml (100 units / 1ml syringe)
- 5.0mg dose: 2.0ml (entire vial)
Storage After Reconstitution
- Temperature: 2-8Β°C (refrigerated, do not freeze)
- Duration: Use within 28 days of reconstitution
- Light Protection: Store in original vial, protect from light
- Contamination Prevention: Use sterile technique for each withdrawal
Research Monitoring Parameters
Recommended monitoring in research protocols:
- Baseline: Body weight, glucose levels, lipid panel
- Weekly: Body weight, food intake, adverse observations
- Monthly: Glucose, HbA1c (if applicable), lipids
- Quarterly: Comprehensive metabolic panel
Dose Adjustments
Research protocols may require dose modifications:
- GI Intolerance: Extend titration period or reduce dose
- Hypoglycemia: Reduce dose or adjust concomitant treatments
- Inadequate Response: May increase to maximum studied dose (15mg)
- Adverse Events: Reduce dose or discontinue per protocol
π Research Best Practices
Tirzepatide's extended half-life (~5 days) means steady-state concentrations are reached after 4-5 weeks. Researchers should allow adequate time between dose escalations to assess full effects. The once-weekly dosing schedule improves compliance in long-term studies compared to daily peptides.
Technical Specifications
Product Information
| Product Name: |
Tirzepatide |
| CAS Number: |
2023788-19-2 |
| Molecular Formula: |
Cβββ
HβββNβ
βOββ |
| Molecular Weight: |
4813.5 g/mol |
| Sequence Length: |
39 amino acids |
| Appearance: |
White to off-white lyophilized powder |
| Solubility: |
Soluble in water, bacteriostatic water, saline |
Quality Control Specifications
| Purity (HPLC): |
β₯99.0% |
| Typical Purity: |
99.2-99.5% |
| Peptide Content: |
β₯95% (by peptide content assay) |
| Water Content: |
β€5.0% (Karl Fischer) |
| Acetate Content: |
β€15.0% |
| TFA Content: |
β€0.1% |
| Endotoxin: |
<0.1 EU/mg |
| Sterility: |
Passes USP <71> sterility test |
Amino Acid Sequence
Tirzepatide Sequence (39 amino acids):
H-Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-OH
Modified with C20 fatty diacid moiety at Lys20 for extended half-life
Pharmacological Properties
| Mechanism: |
Dual GIP/GLP-1 receptor agonist |
| GIP Receptor Affinity: |
ECβ
β = 0.06 nM |
| GLP-1 Receptor Affinity: |
ECβ
β = 0.24 nM |
| Half-Life: |
~5 days (subcutaneous) |
| Tmax: |
8-72 hours |
| Bioavailability: |
80% (subcutaneous) |
| Protein Binding: |
~99% (albumin) |
Storage Conditions
| Lyophilized Storage: |
-20Β°C to -80Β°C |
| Lyophilized Stability: |
24+ months at -20Β°C |
| Reconstituted Storage: |
2-8Β°C (refrigerated) |
| Reconstituted Stability: |
28 days at 2-8Β°C |
| Shipping: |
Cold chain with ice packs |
| Light Sensitivity: |
Protect from light |
Package Contents
- 1 x Tirzepatide 5mg vial (lyophilized)
- Certificate of Analysis (COA)
- HPLC chromatogram
- Mass spectrometry data
- Reconstitution guide
- Storage instructions
Analytical Methods
HPLC Analysis:
- Method: Reversed-phase HPLC
- Column: C18, 4.6 x 250mm, 5ΞΌm
- Mobile Phase: Acetonitrile/water gradient with TFA
- Detection: UV at 220nm
- Flow Rate: 1.0 ml/min
Mass Spectrometry:
- Method: ESI-MS or MALDI-TOF
- Expected m/z: 4813.5 Β± 2.0
- Ionization: Positive mode
Regulatory Status
| FDA Status: |
Approved for diabetes/obesity (Mounjaro/Zepbound) |
| Research Status: |
For laboratory research use only |
| DEA Schedule: |
Not a controlled substance |
| Export Restrictions: |
Check local regulations |
Safety Data
- Hazard Classification: Not classified as hazardous
- Handling: Use standard laboratory safety practices
- PPE: Lab coat, gloves, safety glasses recommended
- Disposal: Follow institutional guidelines for peptide waste
- SDS: Available upon request
π Quality Guarantee
Every batch of tirzepatide is tested by independent third-party laboratories. We provide complete analytical documentation including COA, HPLC chromatogram, and mass spectrometry data. If you have any questions about specifications or need additional analytical data, please contact our technical support team.
Tirzepatide Research & Clinical Studies
The following information is based on published scientific research and clinical studies.
All research cited is from peer-reviewed journals and represents current scientific understanding
of this compound's mechanisms and effects.
Superior Weight Loss Efficacy
Tirzepatide has demonstrated superior weight loss compared to single GLP-1 agonists. The SURMOUNT-1 trial showed participants achieved an average weight loss of 20.9% with the 15mg dose over 72 weeksβsignificantly higher than semaglutide's 14.9%.1
The dual GIP/GLP-1 mechanism provides synergistic effects on appetite suppression and energy expenditure. GIP receptor activation enhances the metabolic effects of GLP-1, leading to greater weight loss and improved body composition.2
Head-to-head trials (SURPASS-2) comparing tirzepatide to semaglutide showed tirzepatide produced 5-7 kg more weight loss at comparable doses, establishing it as the most effective incretin-based therapy currently available.3
Glycemic Control
Tirzepatide produces exceptional glycemic improvements with HbA1c reductions of 2.0-2.5% in clinical trialsβsuperior to all other diabetes medications. The SURPASS program demonstrated that 51-62% of participants achieved HbA1c below 5.7% (non-diabetic range).4
The dual incretin mechanism enhances glucose-dependent insulin secretion while suppressing glucagon more effectively than GLP-1 agonists alone. This results in better fasting and postprandial glucose control.5
Research indicates potential beta cell preservation and improved insulin sensitivity, suggesting disease-modifying effects beyond glucose lowering.6
Cardiovascular & Metabolic Benefits
Tirzepatide improves multiple cardiovascular risk factors including blood pressure, lipids, and inflammatory markers. Studies show 7-10 mmHg reductions in systolic blood pressureβgreater than other GLP-1 agonists.7
The peptide significantly improves lipid profiles with reductions in triglycerides (20-30%), LDL cholesterol, and increases in HDL cholesterol. These improvements are partially independent of weight loss.8
Research demonstrates reduced inflammatory markers (CRP, IL-6) and improved endothelial function, suggesting direct vascular protective effects beyond metabolic improvements.9
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
- Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515.
- Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide. Lancet. 2021;397(10285):1687-1699.
- Del Prato S, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021;398(10313):1811-1824.
- Nauck MA, et al. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes. Diabetologia. 2021;64(6):1187-1197.
- Thomas MK, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function. Diabetes Care. 2021;44(10):2327-2335.
- Sattar N, et al. Tirzepatide cardiovascular event risk assessment. Lancet Diabetes Endocrinol. 2022;10(1):12-14.
- Hartman ML, et al. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis. Diabetes Care. 2020;43(6):1352-1355.
- Heise T, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function. Diabetes Obes Metab. 2022;24(11):2310-2320.
β οΈ Research Disclaimer
This information is provided for educational and research purposes only. These studies
were conducted in laboratory settings and/or clinical trials. This product is intended
solely for research use and is not approved for human consumption or clinical applications.
Customer Reviews
4.8
β
β
β
β
β
Based on 127 reviews
Superior to Semaglutide in Our Studies
We've been using tirzepatide in our metabolic research for 6 months now, and the results are consistently impressive. The dual GIP/GLP-1 mechanism provides more robust metabolic effects compared to semaglutide in our models. Purity is excellent (verified by our in-house HPLC), and the COA documentation is thorough. The 5-day half-life makes weekly dosing protocols much more practical than daily peptides. Highly recommend for serious metabolic research.
Excellent Quality, Fast Shipping
Ordered for my dissertation research on incretin biology. Product arrived within 48 hours with proper cold chain packaging. Reconstituted easily and remained stable throughout my 4-week study. The included documentation (COA, HPLC, MS data) was essential for my thesis committee. Results were reproducible across multiple batches. Will definitely order again for future studies.
Best Tirzepatide Source We've Found
After trying 3 different suppliers, this is by far the highest quality tirzepatide we've tested. HPLC shows 99.3% purity (we verify all peptides in-house). No degradation products visible. Reconstitutes to a perfectly clear solution. We've now ordered 6 times and every batch has been consistent. Customer service is also excellent - they answered technical questions promptly. This is now our go-to supplier for all GLP-1/GIP research.
Good Product, Minor Packaging Issue
The tirzepatide itself is excellent quality - verified purity and works great in our assays. Only issue was one vial arrived with a slightly loose cap (still sealed, but not as tight as others). Contacted customer service and they immediately sent a replacement. Product quality is top-notch, just a minor packaging concern that was quickly resolved. Would order again.
Perfect for Teaching Labs
I use this tirzepatide for my graduate-level pharmacology course. Students learn about incretin biology and dual-agonist mechanisms. The quality is consistent enough that students get reproducible results in their experiments. The documentation is also excellent for teaching purposes - students can see real HPLC and MS data. Price point is reasonable for academic budgets. Highly recommend for educational research settings.
Reliable Supply for Our Research Pipeline
Our company is developing next-generation metabolic therapies, and we use tirzepatide as a benchmark compound. We've ordered 20+ vials over the past 3 months and every batch has been consistent. The batch-to-batch variability is minimal, which is critical for our comparative studies. Shipping is fast and reliable. Customer service helped us set up a research account for easier ordering. Excellent supplier for ongoing research needs.
π Review Policy
All reviews are from verified purchasers who have used this product for legitimate research purposes. We do not accept reviews for non-research use. Reviews are moderated to ensure they comply with our terms of service and applicable regulations.
